News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NanoViricides, Inc. (NNVC.PK) Reports That the DengueCide™ Orphan Drug Application has Been Submitted and Received by the European Medicines Agency


9/3/2013 12:26:39 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that the European associates of the consulting firm Cote´ Orphan Consulting, on behalf of NanoViricides, have submitted an Orphan Drug Application to the European Medicines Agency (EMA) for DengueCide™, a drug candidate for the treatment of dengue and dengue hemorrhagic fever. The Company previously engaged the consulting firm Cote´ Orphan Consulting (COC), headed by Dr. Tim Cote´, to assist with the DengueCide orphan drug applications. The Company, in consultation with COC, has determined that its current lead DengueCide drug candidate is eligible for orphan drug status application in the European Union. The Company has recently received Orphan Drug Designation for DengueCide from the US FDA.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES